Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Company profile
Ticker
IRWD
Exchange
Website
CEO
Mr. Thomas A. McCourt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SupCor, Inc., Supcor, Inc., SUPCOR, INC.
SEC CIK
Corporate docs
Subsidiaries
Ironwood Pharmaceuticals Securities Corporation • Ironwood Pharmaceuticals GmbH • VectivBio AG • VectivBio Comet AG • GlyPharma Therapeutic Inc • VectivBio US, Inc. ...
IRS number
43404176
IRWD stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
30 Sep 24
8-K
Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
8 Aug 24
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 24
8-K
Departure of Directors or Certain Officers
20 Jun 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
9 May 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
10-K
2023 FY
Annual report
16 Feb 24
Transcripts
IRWD
Earnings call transcript
2024 Q2
8 Aug 24
IRWD
Earnings call transcript
2024 Q1
9 May 24
IRWD
Earnings call transcript
2023 Q4
15 Feb 24
IRWD
Earnings call transcript
2023 Q3
9 Nov 23
IRWD
Earnings call transcript
2023 Q2
8 Aug 23
IRWD
Earnings call transcript
2023 Q2
8 Aug 23
IRWD
Earnings call transcript
2023 Q1
4 May 23
IRWD
Earnings call transcript
2023 Q1
4 May 23
IRWD
Earnings call transcript
2022 Q4
16 Feb 23
IRWD
Earnings call transcript
2022 Q3
3 Nov 22
Latest ownership filings
SC 13G/A
STATE STREET CORP
16 Oct 24
4
ALEXANDER J DENNER
18 Sep 24
4
Minardo John
14 Aug 24
4
Ronald Silver
14 Aug 24
144
Notice of proposed sale of securities
9 Aug 24
4
Jay Shepard
21 Jun 24
4
Andrew Dreyfus
21 Jun 24
4
Jon R Duane
21 Jun 24
4
Julie McHugh
21 Jun 24
4
Catherine Moukheibir
21 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 121.54 mm | 121.54 mm | 121.54 mm | 121.54 mm | 121.54 mm | 121.54 mm |
Cash burn (monthly) | (no burn) | 51.71 mm | (no burn) | 82.88 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | 347.59 mm | n/a | 557.07 mm | n/a | n/a |
Cash remaining | n/a | -226.05 mm | n/a | -435.53 mm | n/a | n/a |
Runway (months of cash) | n/a | -4.4 | n/a | -5.3 | n/a | n/a |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 227 |
Opened positions | 28 |
Closed positions | 62 |
Increased positions | 90 |
Reduced positions | 78 |
13F shares | Current |
---|---|
Total value | 1.06 tn |
Total shares | 171.48 mm |
Total puts | 28.50 k |
Total calls | 11.23 mm |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
BLK BlackRock | 22.88 mm | $149.16 bn |
Vanguard | 21.56 mm | $140.59 bn |
Sarissa Capital Management | 16.39 mm | $106.86 bn |
STT State Street | 9.24 mm | $60.26 bn |
Pacer Advisors | 8.91 mm | $58.08 bn |
Renaissance Technologies | 8.57 mm | $55.89 bn |
Armistice Capital | 7.80 mm | $50.86 bn |
LSV Asset Management | 6.07 mm | $39.59 mm |
MS Morgan Stanley | 4.86 mm | $31.69 bn |
Braidwell | 4.44 mm | $28.94 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Sep 24 | Denner Alexander J | Class A Common Stock | Grant | Acquire A | No | No | 0 | 3,282 | 0.00 | 152,104 |
12 Aug 24 | Ronald Silver | Class A Common Stock | Sell | Dispose S | No | No | 4.27 | 3,107 | 13.27 k | 158,370 |
12 Aug 24 | Minardo John | Class A Common Stock | Sell | Dispose S | No | No | 4.27 | 9,910 | 42.32 k | 284,661 |
18 Jun 24 | Shepard Jay | Class A Common Stock | Grant | Acquire A | No | No | 0 | 24,311 | 0.00 | 126,555 |
18 Jun 24 | Dreyfus Andrew | Class A Common Stock | Grant | Acquire A | No | No | 0 | 24,311 | 0.00 | 188,230 |
News
Leerink Partners Initiates Coverage On Ironwood Pharmaceuticals with Market Perform Rating, Announces Price Target of $5
9 Sep 24
Wells Fargo Maintains Overweight on Ironwood Pharmaceuticals, Lowers Price Target to $12
9 Aug 24
Ironwood Q2 Earnings & Revenues Fall Shy of Estimates
9 Aug 24
Craig-Hallum Maintains Buy on Ironwood Pharmaceuticals, Lowers Price Target to $10
9 Aug 24
Ironwood Has Revised Its FY 2024 Financial Guidance Due To Continued Linzess Pricing Pressure Due To Higher-than-expected Medicaid Utilization Trends For FY 2024, It Expects Sales Of $350M-$375M Compared To Prior Range Of $405M-$425M And Consensus Of $410.05M
8 Aug 24